Views on Zydus Cadila receives Market Authorisation (MA) from USFDA for Morphine Sulfate ER Tablets: Angel Broking

Views of Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking)

Zydus Cadila receives Market Authorisation (MA) From USFDA for Morphine Sulfate ER Tablets:

Zydus Cadila received Market Authorisation (MA) from USFDA for Morphine sulfate ER Tablets. The drug is indicated for treatment of chronic pain related to cancer. The product category has around 4-5 players already there. The drug according to our calculations can contribute around US$20-30mn on sales in FY2016. We maintain our NEUTRAL rating on the stock.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.1825.45 as compared to the previous close of Rs. 1796.9. The total number of shares traded during the day was 14785 in over 1257 trades.

The stock hit an intraday high of Rs. 1852 and intraday low of 1799.05. The net turnover during the day was Rs. 27087609.

Source : Equity Bulls

Keywords